Tirzepatide, a dual GLP-1/GIP agonist, has produced up to 19.7% weight loss and reduced T2D progression in adults; after 17 weeks risk of T2D (2.4% tirzepatide group and 13.7% placebo group, hazard ratio, 0.12; 95% CI, 0.1 to 0.2; p < 0.001) [40]. Here, GLP1R is linked to type 2 diabetes mellitus.